Module

Advanced Colorectal Cancer and Novel Therapies

Source: Research Priorities in Colorectal Cancer: Recommendations of the Scientific Leadership Council in GI Cancer of the Coalition of Cancer Cooperative Groups

Advanced Colorectal Cancer and Novel Therapies

Faculty:

Daniel G. Haller, MD

CME CREDIT INFORMATION

Release Date: 10/10/07

Expiration Date: 10/09/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe prognostic factors for patients with metastatic colorectal cancer
Discuss efforts to overcome drug resistance in colorectal cancer
Summarize studies of therapeutic approaches for patients with liver metastases from colorectal cancer
Describe clinical trial results of targeted biologic agents for the treatment of metastatic colorectal cancer

Topics covered include:

Introduction
Prognostic Information in Metastatic Disease
OPTIMOX1
Novel Therapies in CRC
Overcoming Drug Resistance
Individualizing Therapy
CRC Metastatic to the Liver
Bevacizumab in mCRC
Cetuximab in mCRC
Panitumumab in mCRC
Recommendations for Clinical Trials
Priority Issues: Advanced CRC and Novel Therapies

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.